TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT
CAS: 13492-01-8
Molecular Formula: C9H13NO4S
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT - Names and Identifiers
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT - Physico-chemical Properties
| Molecular Formula | C9H13NO4S |
| Molar Mass | 231.27 |
| Solubility | Soluble in water; very slightly soluble in ethanol (96%) and in ether . |
| Appearance | White solid. |
| Color | White |
| Storage Condition | 15-25°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 3 months. |
| Use | Tranylcypromine is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1) with a rapid onset of activity. |
| In vitro study | Tranylcypromine (10 nM to 10 µM) exerts neuroprotective effects against toxicity induced by human Aβ(1-42) oligomers independently from the presence of glial cells. Tranylcypromine (100 μM) significantly protects RGCs from glutamate neurotoxicity-induced apoptosis as well as apoptosis induced by oxidative stress. Tranylcypromine promotes mitogen-activated protein kinase 12 (p38 MAPKγ) expression under conditions of glutamate (Glu)-induced stress. Besides, tranylcypromine contributes to RGC survival via alterations of p38 MAPKγ activity. |
| In vivo study | Tranylcypromine treatment significantly and substantially reduces the lesion size and improves generalized hyperalgesia in a dose-dependent fashion in mice with induced endometriosis. In addition, tranylcypromine treatment results in reduced immunoreactivity to biomarkers of proliferation, angiogenesis, and H3K4 methylation, leading to arrested EMT and lesion growth. Tranylcypromine (500 mM) injection exerts neuroprotective effects within intracellular apoptotic signaling pathways and suppresses morphologic changes in the retina of the rat, suppresses caspase 3 activity and recovers p38 MAPKγ expression in the retina after NMDA-induced injury, and enhances RGC survival after retinal injury via the attenuation of NMDA neurotoxicity. Tranylcypromine (10 µg/g) causes an approximate and significant doubling of labeled cells in the combined brain regions examined, as detected by BrdU immunohistochemistry. Tranylcypromine causes the greatest increase in cell proliferation in the cerebellum. |
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | 23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. |
| Safety Description | S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | GZ2625000 |
| HS Code | 2921490002 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT - Reference
| Reference Show more | 1: Gahr M, Schönfeldt-Lecuona C, Kölle MA, Freudenmann RW. Intoxications with the monoamine oxidase inhibitor tranylcypromine: an analysis of fatal and non-fatal events. Eur Neuropsychopharmacol. 2013 Nov;23(11):1364-72. doi: 10.1016/j.euroneuro.2013.05.009. Epub 2013 Jun 19. Review. PubMed PMID: 23791433. 2: Krings-Ernst I, Ulrich S, Adli M. Antidepressant treatment with MAO-inhibitors during general and regional anesthesia: a review and case report of spinal anesthesia for lower extremity surgery without discontinuation of tranylcypromine. Int J Clin Pharmacol Ther. 2013 Oct;51(10):763-70. doi: 10.5414/CP201898. Review. PubMed PMID: 23993253. 3: Gahr M, Schönfeldt-Lecuona C, Kölle MA, Freudenmann RW. Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry. 2013 Jun;46(4):123-9. doi: 10.1055/s-0032-1333265. Epub 2013 Jan 28. Review. PubMed PMID: 23359339. 4: Iwersen S, Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J Anal Toxicol. 1996 Sep;20(5):301-4. Review. PubMed PMID: 8872238. 5: Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. J Psychiatry Neurosci. 1992 Nov;17(5):206-14. Review. PubMed PMID: 1362653; PubMed Central PMCID: PMC1188458. |
TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.744 ml | 13.719 ml | 27.438 ml |
| 5 mM | 0.549 ml | 2.744 ml | 5.488 ml |
| 10 mM | 0.274 ml | 1.372 ml | 2.744 ml |
| 5 mM | 0.055 ml | 0.274 ml | 0.549 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Spot supply
Product Name: TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT Visit Supplier Webpage Request for quotationCAS: 13492-01-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: TRANS-2-PHENYLCYCLOPROPYLAMINE HEMISULFATE SALT Visit Supplier Webpage Request for quotationCAS: 13492-01-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History